First-Tier Array CGH in Clinically Variable Entity Diagnosis: 22q13.3 Deletion Syndrome by Budisteanu, Magdalena et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
First-Tier Array CGH in Clinically 
Variable Entity Diagnosis: 22q13.3 
Deletion Syndrome
Magdalena Budisteanu, Andreea Tutulan-Cunita, 
Ina Ofelia Focsa, Sorina Mihaela Papuc and Aurora Arghir
Abstract
Phelan-McDermid (PMS) or 22q13 deletion syndrome (OMIM 606232) is a rare 
genetic disorder with highly variable clinical presentation. The phenotype includes 
generalized neonatal hypotonia, developmental delay with intellectual disability 
and delayed speech, mild dysmorphic features, and autistic behavior. The genetic 
defects of PMS consist of 22q13.3 deletions or chromosomal structural rearrange-
ments involving SHANK3 gene; the loss of function mutations of SHANK3 gene 
was reported in a minority of cases. The 22q13.3 deletions vary in size, from 0.2 
to over 9 Mb, and, although larger deletions are generally associated with more 
severe phenotypes, the genotype-phenotype correlations are not clear-cut for all 
patients. SHANK3 is considered the main candidate gene for the neurologic features 
of PMS. PMS is a rare disorder, often underdiagnosed. There are no established 
clinical diagnostic criteria for PMS. The genetic tests typically used are chromo-
somal microarray and multiplex ligation-dependent probe amplification (MLPA) or 
fluorescent in situ hybridization (FISH) for copy number analysis of SHANK3 gene; 
next-generation sequencing (NGS) or Sanger sequencing is used for pathogenic 
mutation screening of SHANK3. In this chapter, we report three cases with PMS 
and summarize the clinical and genetic diagnostic approaches of this condition, 
highlighting the role of chromosomal microarray technology in the identification of 
rare, but significantly impacting patient’s life, DNA copy number abnormalities.
Keywords: chromosomal microarray, deletions, intellectual disability, speech delay, 
autistic features
1. Introduction
Phelan-McDermid or 22q13 deletion syndrome (OMIM 606232, PMS) is a 
genetic disorder characterized by a wide phenotypic spectrum that includes 
neonatal hypotonia, global developmental delay with cognitive deficits, absent to 
severely delayed speech (usually, more advanced perceptive language than expres-
sive language), dysmorphic features (dolichocephaly, large or malformed ears, full 
brows, full cheeks, bulbous nose, pointed chin), behavioral abnormalities with 
autistic features (poor eye contact, stereotypic movements, impaired social interac-
tions, aggressive behavior), and various neurological problems (reduced perception 
of pain, seizures, abnormal patterns of movements, habitual chewing or mouthing, 
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inability to regulate sweating) [1–3]. Patients with PMS are highly unlikely to ever 
function independently. Less often, congenital kidney anomalies [3], arachnoid 
cysts [1], and higher frequency of other pathological conditions (gastrointestinal 
disease, upper respiratory tract infections, ventriculomegaly, dysmyelination, mor-
phological changes of the corpus callosum [4]) are described. No life-threatening 
malformations are associated with this disorder; however, as the number of patients 
reaching older ages is small, there may be yet a not identified potential for develop-
ing life-threatening conditions. Its incidence is not known, but the PMS Foundation 
estimates approximately 1949 patients worldwide, as of September 2018 on http://
www.22q13.org; the prevalence of subjects with PMS in patients with neurodevel-
opmental delay was estimated at 0.27% [5]; it is present with equal frequency in 
both sexes.
The genetic anomalies associated with PMS involve 22q13.3 region, leading to 
SHANK3 gene haploinsufficiency, in the vast majority of cases. Simple deletions 
were described in ~79% of patients; deletions generated by unbalanced transloca-
tions, ring chromosomes, or complex chromosomal rearrangements were reported 
in ~18% of patients. In addition, mutations involving SHANK3 gene were detected 
in a minority of patients (~3%) with PMS phenotype [6].
Chromosome 22q13.3 deletions range from 0.2 to over 9 Mb [5, 7]. A critical 
region for PMS was refined in 2002 by Anderlid et al. [8], to 100 kb containing 
SHANK3, ACR, and RABL2B, with SHANK3 being the candidate gene for the 
clinical features of PMS. In 2001, Bonaglia et al. [9] reported a patient with a 
phenotype consistent with PMS, bearing a translocation t(12;22) which disrupted 
SHANK3 gene only. Subsequent studies, reporting small chromosomal deletions 
and mutations, brought further evidence supporting the role of SHANK3 gene 
in PMS neuropsychiatric phenotype [10, 11]. Both contiguous gene deletion at 
22q13.3, including SHANK3, and pathogenic variants of SHANK3 were reported in 
PMS. Rarely, interstitial deletions with intact SHANK3 and PMS-like phenotypes 
have been described, indicating that haploinsufficiency of other genes or a posi-
tional effect influencing SHANK3 expression may cause the same phenotype in 
some patients [12–14].
SHANK3 encodes for a scaffold protein that connects ion channels and receptors 
in the postsynaptic density of glutamatergic synaptic membrane to the cytoskel-
eton, thus participating in a signal transduction pathway highly relevant to various 
forms of autism spectrum disorder (ASD) [1, 4, 15, 16]. Neurons differentiated 
from induced pluripotent stem cells from patients with PMS have reduced SHANK3 
expression and major defects in excitatory, but not inhibitory synaptic transmis-
sion [17]. Yi et al. [18] demonstrated, in 2016, that SHANK3 haploinsufficiency 
decreases Ih channel function, leading to altered synaptic function.
The deletions in PMS patients span a large genomic region and encompass 
numerous protein coding genes; many of these genes are highly expressed in the 
brain [19]. Genotype-phenotype correlations connected larger deletion sizes with 
the severity of the developmental profile, hypotonia, increased number of medical 
comorbidities, dysmorphic features, and absence of an ASD diagnosis [12]; on the 
contrary, other studies suggested more severe autistic phenotype in patients with 
larger deletions, or even no association at all [4]. Additionally, it has been hypoth-
esized that the increase in the deletion size may attenuate the effects of SHANK3 
deficiency, i.e., autistic features, due to additional genes concomitant deletions; 
also, the severe developmental and language impairments observed in patients with 
larger deletions make the evaluation of autistic features more difficult [12].
The genetic anomalies in PMS are de novo (80% of cases) or inherited from par-
ents with balanced translocations, inversions, or mosaics (20% of cases); Sarasua 
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et al. [12] reported a 75% inheritance of the abnormal chromosome from the father, 
but no association with parental age at conception. PMS has been described both in 
mosaic and non-mosaic forms.
PMS is a rare disorder, with a broad phenotypic spectrum, that often goes 
underdiagnosed. As there are no specific clinical features suggestive for PMS, the 
diagnosis is genetic. Chromosomal microarray is the method most commonly used, 
as a first-tier approach; various techniques can be used for confirmation of copy 
number imbalance (fluorescent in situ hybridization (FISH), multiplex ligation-
dependent probe amplification (MLPA), or qPCR. We report three cases with PMS 
and summarize the clinical and genetic diagnostic approaches of this condition, 
highlighting the role of array-based comparative genomic hybridization (array 
CGH) technology in identification of rare, but significantly impacting patient’s life, 
DNA copy number abnormalities.
2. Materials and methods
Our patients have been referred to clinical and genetic evaluation for develop-
mental delay and behavior problems. The patients have been clinically evaluated by 
a multidisciplinary team including child psychiatry and child neurology special-
ists, as well as a psychologist. Array-based comparative genomic hybridization 
(array CGH) using two oligonucleotide platforms (180 and 60 K) was performed 
on genomic DNA (gDNA) isolated from peripheral blood, as recommended by 
manufacturer (Agilent Technologies, Agilent Oligonucleotide Array-Based CGH for 
Genomic DNA Analysis Enzymatic Labeling for Blood, Cells, or Tissues Protocol, 
Version 7.3, March 2014). FISH using bacterial artificial chromosome (BAC) probes 
RP11-316I10 (22q11.21), CTA799F10, and cosmide n85a3 (22q13.33) was carried out 
according to standard protocol, in probands and parents.
All three patients were born to healthy, non-consanguineous parents, follow-
ing uncomplicated pregnancies and with no perinatal events. Patients 1 and 2 are 
siblings; patient 3 is the second child, having a healthy sibling. Table 1 summarizes 
the clinical characteristics of our patients.
The first patient, a 4-year-old boy, with a height of 91 cm (Pc 5), weight of 16 kg 
(Pc 25), and occipitofrontal circumference (OCP) of 49 cm (Pc 25), presented 
delayed psychomotor development (walked alone at 18 months, says no syllables); 
minor dysmorphic features: hypoplastic helix, bilateral epicanthus, long eyelashes, 
and thin upper lip; bilateral 2nd–3rd toes partial cutaneous syndactyly; and sacral 
dermal sinus. Neurological evaluation revealed gross and fine motor inabilities and 
absent speech. Psychiatric and psychologic evaluation showed severe intellectual 
disability, autistic features (absent psychical and visual contact, stereotypic play, 
no social interactions), and hyperkinesia with aggressive behavior. He had a history 
of repeated respiratory infections. Electroencephalography (EEG) and abdominal 
ultrasound investigations were normal. Brain MRI revealed minimal dysmyelin-
ation and corpus callosum hypotrophy. Metabolic screening tests for Pompe disease, 
neurolipidosis, mucopolysaccharidosis, glycoproteinosis, mucolipidosis type I, and 
serum amino acids were normal.
The second patient, a 2-year-old sister of patient 1, with a height of 81 cm (Pc 10),  
weight of 11.2 kg (Pc 25), and occipitofrontal circumference (OCP) of 47 cm (Pc 
25–50), presented moderately delayed psychomotor development (walked alone 
at 1.5 year old; had first syllables at 6 months without any progression afterward), 
micrognathia, and bilateral 2nd–3rd toes partial cutaneous syndactyly. Neurological 
examination showed gait disorders (an instable gait, with left lower limb rotated 
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outside) and speech delay (she says only few syllables). Psychiatric and psychologic 
evaluation revealed moderate developmental delay and autistic features (did not 
respond to commands; was not sociable, playing alone, and imitating only few 
actions). Her history included prolonged neonatal icterus (Crigler-Najjar syndrome 
type II). Her EEG was normal.
The third patient, an 11-year-old girl, presented delayed psychomotor develop-
ment; she walked alone at 2 years and said first syllables after 5 years. The neuro-
logical evaluation at 11 years and 7 months showed severe intellectual disability and 
severe speech delay (she said only few mono- and disyllabic words, understood few 
simple orders). Brain MRI showed cerebellar subarachnoid cyst.
All three patients were investigated with genome-wide array CGH platforms. 
Array CGH experiments were performed using SurePrint G3 Human CGH 
Microarray Kits 180 K containing 170,334 distinct oligonucleotide probes (patients 
1 and 2) and 60 k containing 55,077 distinct oligonucleotide probes (patient 3). 
The median probe spacing in RefSeq genes was 11 kb for 180 K platform and 33 kb 
for 60 K platform, respectively. The genomic gDNA was extracted using PureLink 
Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific); the concentration 
and quality of gDNA were assessed using a NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific). Normal human gDNAs (Agilent Human Reference 
DNA Male or Female, according to the sex of the patient) were used as reference 
DNA. The experimental procedures were conducted using 1000 ng gDNA for 
180 K microarray kit and 500 ng for 60 K microarray kit, for each sample (test 
and reference). After the enzymatic digestion of gDNA with AluI and RsaI, the 
reference DNA samples were labeled with cyanine 5-deoxyuridine triphosphate 
(Cy5-dUTP) and the patients DNA samples with Cy3-dUTP, respectively, using the 
Features Patient 1 Patient 2 Patient 3
Neonatal hypotonia + + +
Normal to accelerated growth + + +
Absent to severely delayed speech + + +
Global developmental delay + + +
Minor dysmorphic facial features + + +
Behavior characteristics
• Autistic-like affect and behavior + + +
• Mouthing or chewing nonfood items — — —
• Decreased perception of pain NA NA NA
Relatively large and fleshy hands + + —
Dysplastic toenails — — —
sacral dimple + — —
Decreased perspiration NA NA NA
Feeding difficulties — — —
Strabismus — — —
Renal problems — — —
Seizures — — —
NA, not assessed; +, present; −, absent.
Table 1. 
Clinical characteristics of our patients.
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SureTag DNA Labeling Kit (Agilent Technologies). The labeled test and reference 
samples were pooled and purified together using Agilent Purification Columns. The 
DNA mixture was combined with Cot-1 DNA (Agilent Technologies), 10× aCGH 
blocking agent, and 2× HI-RPM hybridization buffer (Agilent Technologies); the 
mixture was dispensed to a microarray slide, assembled with an Agilent hybridiza-
tion chamber, and incubated at 67°C for 24 h at 20 rpm. The hybridization was 
followed by a two-step washing procedure using Wash Buffer 1 and Wash Buffer 2 
(Agilent Technologies). The microarray slides were scanned with Agilent SureScan 
Microarray Scanner system, and the data were extracted and analyzed using Agilent 
Cytogenomics software (Agilent Technologies). Copy number variations (CNVs) 
were called if they encompassed at least three consecutive probes with a log2 ratio 
value over 0.25 or below −0.25. For CNV clinical interpretation, public databases 
were used: UCSC (http://genome.ucsc.edu, accessed July 15, 2019); DGV (http://
dgv.tcag.ca/dgv/app/), OMIM (http://www.omim.org/); DECIPHER (http://deci-
pher.sanger.ac.uk/), and PubMed (https://www.ncbi.nlm.nih.gov/pubmed/).
3. Results and discussion
PMS has been under continuous investigation since its description [20, 21] that 
benefited, in many cases, by the strong cooperation of the PMS Foundation. Most 
of the patients were recruited in the USA [7, 12, 20–23] and Western Europe  
[9, 24–29]; there are also reports from Korea [30] and China [31]. PMS seems to be 
underdiagnosed in many parts of the world. However, the wide use of chromosomal 
microarray as a first-tier test for patients with neurodevelopmental disorders, 
autism, and congenital malformations [32] has greatly improved both diagnostic 
sensitivity and yield.
The array CGH results of our patients revealed deletions of 22q13 includ-
ing SHANK3 gene. The genomic profiling of the two siblings (patients 1 
and 2) revealed an identical 1.38 Mb interstitial duplication and a 1.565 Mb 
distal deletion: arr[GRCh37] 22q13.31q13.33(48202588_49585589)x3 and 
22q13.33(49628598_51193680)x1 (Figure 1a). The deletion was confirmed by 
FISH. The duplication contained 2 miRNAs and FAM19A5, a gene coding a protein 
expressed mainly in the brain, considered a putative immunomodulator in nervous 
cells [5], while the 1.56 Mb deleted region included 37 genes, among which are 
ALG12, MLC1, SBF1, SCO2, TYMP, MAPK8IP2, ARSA, SHANK3, ACR, TUBGCP6, 
and CHKB (Figure 1b). Karyotype analysis and FISH testing of both parents 
(CTA799F10 probe, 22q13.33) showed no visible anomalies.
Patient 3 had a 3.514 Mb deletion, arr[GRCh37] 22q13.31q13.33 
(47664025_51178264)x1, containing 41 genes, among which are ALG12, MLC1, 
SBF1, SCO2, TYMP, MAPK8IP2, SHANK3, ARSA, TUBGCP6, and CHKB 
(Figure 2a and b). The result was confirmed by FISH, using RP11-316I10 probe 
(22q11.21) and cosmide n85a3 (22q13.33).
The cytogenetic findings in PMS may be variable. In a study gathering 201 PMS 
patients analyzed by array CGH, the vast majority had 22q13 terminal deletions. 
Duplications, varying in size from 0.02 to 6.84 Mb, localized centromeric to the 
deleted region were detected in 9% of patients [7]. Two of our patients (patients 1 
and 2, siblings) have a similar pattern and a proximal duplication that accompanies 
a terminal deletion. This type of duplication-deletion cytogenetic changes have 
been reported for many chromosomes, and it is most likely mediated by a U-type 
exchange between sister chromatids [33]. Patient 3 had a simple terminal deletion.
22q13 region in the vicinity of SHANK3 gene is rich in genes with a high expres-
sion in the brain and also a high probability of loss of function intolerance [19, 34]. 
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The haploinsufficiency of these genes is considered to contribute not only to the 
variability of the phenotype but also to the neuropsychiatric features of PMS.
Among the genes located on 22q, PARVB and SULT4A1 genes (telomeric to 
SHANK3) have been associated with increased severity of PMS [29]. Mitogen-
activated protein kinase 8-interacting protein 2 (MAPK8IP2) localized centromeric to 
SHANK3 codes a protein with high expressivity in the brain (postsynaptic density);  
experimental animal studies showed that mice lacking MAPK8IP2 had motor and 
cognitive deficits [35]. MLC1 gene variants have been reported as causal for megalen-
cephalic leukoencephalopathy characterized by regression of development. Taking 
Figure 1. 
(a) The genomic profiling of the two siblings (patients 1 and 2) revealing an identical 1.38 Mb interstitial 
duplication and a 1.565 Mb distal deletion and (b) UCSC Genome Browser window showing the genomic 
coordinates of the detected variants.
Figure 2. 
(a) The genomic profiling of the patient 3 showing a 3.514 Mb deletion and (b) UCSC Genome Browser 
window showing the genomic coordinates of the detected variant.
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into account the prevalence of regression symptoms in PMS, the relation between 
deletion of MLC1 gene and regression might bring new insights [35].
Other genes in this region have been involved in particular aspects of PMS (e.g., 
NUP50, CERK, KIAA1644, PHF21B, c22orf9, FBLN1, CELSR1, or miRNA molecules 
located at 22q) [7]. Frye et al. [36] brought evidence that haploinsufficiency of 
genes related to mitochondrial functioning, located at or close to 22q13.3 (e.g., 
TRMU, SCO2, TYMP, CPT1B), may explain a part of the phenotypic variation in 
PMS patients.
PARVB and WNT7B gene loss as well as larger or more proximal deletions of 
22q have been associated with absent speech [5, 7]. In addition, Soorya et al. [10] 
reported in 2013 that expressive and receptive language skills were not significantly 
associated with deletion size. Our patients 1 and 3 had absent speech; patient 2, 
evaluated at 2 years of age, also presented speech delay. The regions deleted in our 
patients did not correlate with the abovementioned genetic regions nor include 
PARVB and WNT7B genes. However, both of our patients exhibited ASD, which 
has been associated with smaller deleted segments [5]. Aggressive behavior, pres-
ent in patient 1, has been assumed to be inversely correlated with the deletion size 
[7]. Brain structural anomalies, among which is corpus callosum hypoplasia, are 
reported in the literature to be present in 25–66% of patients [5]; this anomaly was 
present also in the first patient. Patient 3 has a cerebellar subarachnoid cyst, also 
reported in PMS patients [4]. Patient 2 did not undergo brain MRI.
4. Conclusion
PMS is a rare disorder, with a broad phenotypic spectrum, which often goes 
underdiagnosed. Although the phenotype is clinically heterogeneous, PMS should 
be considered in any patient with global developmental delay, absent or severely 
delayed speech, and autistic behavior, in association with some minor dysmorphic 
features (dolichocephaly, ear anomalies, periorbital fullness, epicanthal folds, 
hypertelorism, long eyelashes, bulbous nose, pointed chin, large fleshy hands) and 
hypotonia. The most common medical complications include seizures, gastrointes-
tinal problems, renal anomalies, and respiratory infections [4]. Brain MRI images 
showed a high prevalence of arachnoid cysts, ventriculomegaly, dysmyelination, 
and morphological changes of the corpus callosum [4]. Clinical practice param-
eters reviewed by Kolevzon et al. [4] aimed to provide guidelines for evaluation 
and monitoring. The clinical evaluation and regular monitoring of patients with 
PMS should include psychiatric, psychological, neurologic, endocrinological, 
cardiologic, gastroenterological, nephrological, and pediatric examinations. After 
a review of all case series reported previously, the authors concluded that there 
are no specific features for the syndrome and the diagnosis of PMS is genetic [4]. 
Recommended genetic tests are chromosomal microarray (as a first-tier test), 
MLPA, and FISH; if these tests are not informative in a patient, mutations should be 
searched by NGS or Sanger sequencing.
Regarding the therapeutic strategy, patients can benefit from early intervention 
targeted to improve their muscle strength and communication abilities, including 
physical, speech, occupational, and behavioral therapies [1]. There are very few 
studies on different medications in patients with PMS [37]. One study investigated 
the effect of intranasal insulin—six individuals with PMS received 0.5–1.5 IU/day 
three times daily for 12 months, with good effects both on motor development and 
cognitive functions [38]. In another study on 25 children with PMS, intranasal 
insulin improved intellectual and behavioral development, especially in children 
older than 3 years, but most results were not statistically significant (Netherlands 
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Trial Registry ID: NTR3758). Studies on mice and human neuronal models brought 
evidence that insulin-like growth factor-1 (IGF-1) reverts synaptic deficits in PMS 
[4, 27], as well as in Rett syndrome [4, 27], most probably due to its positive effects 
on synaptic development, neurogenesis, and brain vessel growth [27]. Clinical 
studies with IGF-1 and related compounds in autism spectrum disorders, including 
PMS, are ongoing.
PMS is a rare disorder with a wide phenotypic spectrum and a large genomic 
landscape. SHANK3 gene is considered the main culprit for the neuropsychiatric 
phenotype; however, its role must be investigated in the broader genetic landscape. 
Insights into the contribution of other genes at 22q13 are gained from genomic pro-
filing, leading to refined genotype-phenotype correlations. PMS clinical diagnosis 
is challenging, as no pathognomonic features are described. Intellectual disability/
global developmental delay, severe speech impairment, autistic features, motor 
impairments, and mild dysmorphic traits stand as the main clinical characteristics.
Genetic diagnosis of PMS has greatly benefited from the introduction of chro-
mosomal microarray. As no characteristic clinical features are described, genomic 
profiling by microarray as a first-tier approach drives the diagnosis. Furthermore, 
the detailed molecular characterization has advanced the understanding of differ-
ent gene contributions to PMS pathogenesis, thus paving the way for identification 
of therapeutic targets.
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